H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $85 from $75 and keeps a Buy rating on the shares. The FDA approval of Merck’s (MRK) subcutaneous Keytruda across 38 tumor indications turns Halozyme’s lawsuit into live multibillion dollar share catalyst, the analyst tells investors in a research note. The firm says the approval ensures that Halozyme’s case is no longer about a theoretical formulation but a major commercial franchise with near-term sales relevance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme price target raised to $80 from $75 at Morgan Stanley
- Halozyme’s Strong Financial Performance and Growth Potential Justifies Buy Rating
- Halozyme Therapeutics’ Earnings Call Highlights Robust Growth
- Halozyme’s Strong Financial Performance and Growth Prospects Lead to Buy Rating and Increased Price Target
- Halozyme’s Strong Financial Performance and Growth Prospects Lead to Buy Rating